Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Aditxt signed a definitive agreement to separate its 100%-owned subsidiary, Ignite Proteomics, in a transaction valuing the proteomics business at approximately $150 million. Ignite will become an independent NYSE-listed company through a newly formed public holding company, while Aditxt remains a separate Nasdaq-listed entity focused on its broader health innovation strategy. The deal is expected to unlock value for Aditxt shareholders, with Ignite equity holders receiving shares of the new public company based on a $10.00 reference price.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.